comprehensive -WSS

comprehensive

author：leisure time 2025-09-07 17:23:37 - browse：656

Microsoft's head of research Peter Lee speaking at STAT Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

SAN FRANCISCO — Surging interest in generative AI among medical professionals since ChatGPT’s launch is perhaps a testament to its potential — but it could also lead clinicians, and patients to experiment with it before there is wider consensus on how to navigate its biases and other pitfalls, Microsoft’s head of research Peter Lee said Thursday at STAT’s Breakthrough Summit.

About a month after OpenAI — Microsoft has a significant financial stake in the company — launched its chatbot in 2022 on November 30, which happened to be Lee’s birthday, he got a note from a doctor friend who said he’d used it so his receptionist could file after-visit summaries for patients. While Lee and a handful of other doctors at Microsoft had been impressed with the GPT-4’s capabilities, they knew it had weaknesses.

“The emotions were really mixed. I mean we were thrilled,” he said, but then “just within minutes there’s a feeling of dread. We had already come to the realization that GPT-4 would be prone to issues, issues of bias, hallucination, mathematical and logical errors,” he said. “And so, there’s an immediate question: ‘Should we allow this to happen?’”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Cheap, fast test for Zika and dengue could cost just $1

WSS

'Essentially witchcraft:' A former naturopath takes on the field

Humana’s losses in Medicare Advantage tank its stock

Health Care Service Corp to buy Cigna Medicare Advantage plans

5 takeaways from STAT's examination of Zynex Medical

California wildfire smoke linked to 52,000 early deaths, study says

Medical device trials still don't enroll enough women, study finds

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

ALS patient reclaims some autonomy thanks to wearable 'robot'

BioMarin wins approval for gene therapy to treat hemophilia A

Study: Why relieving medical debt did not improve financial outcomes

23andMe had bad news about my health. I wish a person had delivered it

5 takeaways from STAT's examination of Zynex Medical

Hollywood unions extend contract negotiations for actors

Coercive sterilizations revealed by STAT prompt outrage

DIEP, the 'gold standard' of breast reconstruction, is under threat

ALS patient reclaims some autonomy thanks to wearable 'robot'

knowledge

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

ALS patient reclaims some autonomy thanks to wearable 'robot'

Pharma companies must ensure equitable access to obesity drugs

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

The system is set up to fail children with medical complexity

Moderna says combo Covid

explore

explore

hotspot

Wikipedia